Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Pancreatic Adenocarcinoma × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 38 Carcinoma, Non-Small-Cell Lung 16 Neoplasm Metastasis 11 Neoplasms 10 Carcinoma, Renal Cell 9 Carcinoma, Hepatocellular 7 Ovarian Neoplasms 6 Colorectal Neoplasms 6 Uveal Melanoma 5 Small Cell Lung Carcinoma 5 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Mesothelioma 4 Lung Neoplasms 4 Diabetes Mellitus, Insulin-Dependent, 12 4 Carcinoma, Merkel Cell 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Sarcoma 3 Prostatic Neoplasms 3 Multiple Myeloma 3 Liver Neoplasms 3 Head and Neck Neoplasms 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Solid Tumor 2 Recurrence 2 Mesothelioma, Malignant 2

Interventions

tocilizumab 1 selicrelumab 1 niraparib 1 durvalumab 1 cobimetinib 1 atezolizumab 1 Tiragolumab 1 Panitumumab 1 PEGPH20 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Leucovorin 1 Ipilimumab 1 Gemcitabine 1 Fluorouracil 1 Bevacizumab 1 4-fluorobenzoyl-TN-14003 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡